
D&D Pharmatech Inc. — Investor Relations & Filings
D&D Pharmatech is a clinical-stage biopharmaceutical company specializing in the development of therapies based on GLP-1 (Glucagon-like peptide-1) and related peptides. The company's pipeline primarily targets metabolic diseases, including obesity and MASH (Metabolic dysfunction-associated steatohepatitis), as well as neurodegenerative disorders. A core competency is its proprietary oral peptide delivery technology. Key candidates in its portfolio include DD01, an injectable dual GLP-1/glucagon receptor agonist for MASH that has received FDA Fast Track Designation, and an oral GLP-1 therapy for obesity. The company operates a global model, funding drug development through specialized subsidiaries, with research functions in Korea and clinical development managed by its US-based team.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 기업설명회(IR)개최 | 2026-06-10 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-06-09 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-06-09 | Korean | |
| 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-06-09 | Korean | |
| 기업설명회(IR)개최 | 2026-06-05 | Korean | |
| 기업설명회(IR)개최 | 2026-06-02 | Korean |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 48020606 | 기업설명회(IR)개최 | 2026-06-10 | Korean | ||
| 48007843 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-06-09 | Korean | ||
| 48007814 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-06-09 | Korean | ||
| 48007804 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-06-09 | Korean | ||
| 47974600 | 기업설명회(IR)개최 | 2026-06-05 | Korean | ||
| 47926452 | 기업설명회(IR)개최 | 2026-06-02 | Korean | ||
| 47078761 | [기재정정]투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline data 수령) | 2026-05-27 | Korean | ||
| 46381718 | 사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-05-18 | Korean | ||
| 46368733 | 분기보고서 (2026.03) | 2026-05-15 | Korean | ||
| 46360438 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-05-15 | Korean | ||
| 39057978 | 증권발행결과(자율공시) (제2회차 CB) | 2026-04-30 | Korean | ||
| 34627555 | 단일판매ㆍ공급계약체결 | 2026-04-16 | Korean | ||
| 34543562 | 주요사항보고서(전환사채권발행결정) | 2026-04-15 | Korean | ||
| 33085400 | 정기주주총회결과 | 2026-03-30 | Korean | ||
| 33085392 | 사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-03-30 | Korean | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Cellectar Biosciences, Inc.
Clinical-stage biopharma developing targeted cancer treatme…
|
CLRB | US | Manufacturing |
|
Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunot…
|
ALCLS | FR | Manufacturing |
|
Cellid Co., Ltd.
Develops immunotherapeutic vaccines for cancer and infectio…
|
299660 | KR | Manufacturing |
|
Cellromax Science Co., Ltd.
Researches and develops health foods, derma-cosmetics, and …
|
471820 | KR | Manufacturing |
|
CellSeed Inc.
Develops and commercializes cell sheet engineering for rege…
|
7776 | JP | Manufacturing |
|
Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmun…
|
068270 | KR | Manufacturing |
|
Celltrion Pharm Inc.
Manufactures and supplies chemical pharmaceuticals and bios…
|
068760 | KR | Manufacturing |
|
CELLUMED CO., LTD.
Develops and manufactures medical devices, tissue grafts, a…
|
049180 | KR | Manufacturing |
|
Celon Pharma S.A.
An integrated pharmaceutical company researching and manufa…
|
CLN | PL | Manufacturing |
|
Celularity Inc
Develops allogeneic cell therapies and biomaterials from th…
|
CELU | US | Manufacturing |
D&D Pharmatech Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/16322/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=16322 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=16322 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=16322 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 16322}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for D&D Pharmatech Inc. (id: 16322)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.